Prostate cancer may respond to more hormone therapy

	Tweet

Suppression of the male hormone androgen in locally advanced prostate cancer appears to be more successful when treatment is prolonged, according to Canadian and US researchers.

In a March 23rd online paper issued by the Journal of Clinical Oncology, Dr. Luis Souhami of Montreal General Hospital and colleagues report on an analysis of data for 189 patients who had taken part in a trial of therapy for locally advanced prostate cancer.

All received radiotherapy followed by goserelin given indefinitely or until disease progression. Surviving patients were followed for an average of 9.6 years and received adjuvant hormone therapy for an average of 2.2 years.

After adjustment for factors including age and the cancers degree of aggression, stratification by hormone therapy duration showed that therapy for more than 5 years was significantly associated with better overall survival and disease-free survival than was shorter duration therapy.

For example, the 5-year overall survival in this group was 100 percent, compared to 71.9 percent in those who received hormone therapy for a year or less. The corresponding survival rate in patients who had received between 1 and 5 years of therapy was 66.7 percent.

However, Dr. Souhami told Reuters Health, “Although our analysis gives strong support to the hypothesis that long-term hormonal therapy leads to better outcome than the standard two- to three-year regimen, it is clear that a well-designed randomized trial is needed to definitively answer this question.”

SOURCE: Journal of Clinical Oncology, March 23, 2009.

RELATED STORIES:
Urine test may detect aggressive prostate tumors   Daily drinking may raise risk of several cancers   Gonorrhea linked to higher prostate cancer risk   Mediterranean Diet May Help Prevent Prostate Cancer   New, Non-invasive Prostate Cancer Test Beats PSA in Detecting Prostate Cancer   First Biomarker Discovered that Predicts Prostate Cancer Outcome   Drug shows promise in prostate cancer spread to bone   Prostate Cancer Genes Behave Like Those in Embryo   Long-Term Survival Probability in Men with Clinically Localized Prostate Cancer   Don’t believe hype about robot prostatectomy: study   Link Uncovered Between Benign Prostatic Hyperplasia, NSAIDs   Mushroom extract may boost prostate cancer drug   Prostate cancer screening still unproven: report   Castrate resistant prostate cancer: New therapeutic approaches   Tissue spacers reduce risk of rectal injury for prostate cancer patients   Study examines the use of a novel suprapubic catheter in suprapubic prostatectomy   STD confirmed to be associated with increased risk of prostate cancer   Researchers find new biomarker for fatal prostate cancer   Finnish researchers find a compound that prevents the growth of prostate cancer cells   Study looks at using the immune system to reduce prostate cancer risk   Strict diet program may help prostate cancer   Variances in patterns of care for patients with prostate cancer failing primary therapy

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]